MedTrace Logo

The New Strategy for Pharmacological Treatment in People With Schizophrenia

NCT00352339 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2009-08-06

No results posted yet for this study

Summary

Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia.

Conditions

Interventions

DRUG

Rispridoen and Aripiprazole

Start with risperidone and switch it to aripiprazole. Flexible dose

DRUG

Risperidne

Start with risperidne and keep it through the end of study. Risperidne:flexible dose

DRUG

Abilify

Start with abilify and keep it through the end of study

Sponsors & Collaborators

  • Inje University

    lead OTHER

Principal Investigators

  • Joo-Cheol Shim, MD,PhD · Clinical Trial Center, Paik hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352339 on ClinicalTrials.gov